1. Yeo MR, Kwak MS, Chung IS, et al. Pharmacologic actions of proton pump inhibitors and acid pump antagonist; implication in the treatment of Helicobacter pylori-associated gastric disease. Korean J Helicobacter Res Pract. 2005; 5:113–123.
2. Chang R, Chung IS, Park SH, et al. Phase III clinical trial of Revaprazan (RevanexⓇ) for gastric ulcer. Korean J Gastrointest Endosc. 2007; 34:312–319.
3. Kim YG, Jang BI, Kim TN. A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection. Gut Liver. 2010; 4:25–30.
Article
4. Oak JH, Chung WC, Jung SH, et al. The effect of acid pump antagonist (Revaprazan, RevanexⓇ) on the result 13 Urea breath test in the patients with Helicobacter pylori associated peptic ulcer disease. Korean J Gastroenterol. 2011; 57:8–13.
5. Rew JS. Clinical use of proton pump inhibitors in gastrointestinal diseases. Korean J Gastroenterol. 2006; 47:181–190.
6. Kim HK, Park SH, Cheung DY, et al. Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010; 25:1618–1625.
Article
7. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Association of Gastroenterology. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2009; 54:269–278.